Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
ABCL, tafasitamab, lenalidomide, diffuse large B-cell lymphoma (DLBCL), NK cell, immunotherapy, phase II
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要